

## Introduction


The Saturation Transfer Difference (STD)<sup>1</sup> NMR is tested as a screening method to identify binding and non-binding fragments against Bromodomain-containing protein 4 (BRD4).<sup>2,3</sup> The results were compared to Surface Plasmon Resonance (SPR)<sup>4</sup> and X-ray<sup>5</sup> data previously acquired in BioFocus.<sup>6</sup> The degree of agreement was assessed.

## STD NMR<sup>1</sup>

- STD NMR is one of the most sensitive techniques in FBLD.
- It utilises the saturation of macromolecule resonances through a train of frequency selective pulses. Saturation is then transferred to bound ligand via <sup>1</sup>H-<sup>1</sup>H cross-relaxation. In the end, free ligand relaxation is detected following the dissociation.
- Due to the saturation it experienced, the binder signals have lower intensity than non-binder's, allowing the distinction between the two in a single experiment.
- Usually NMR screen involves several fragments in a cocktail (5-7) aimed at testing as many compounds as possible using minimum time and material.
- A deconvolution NMR screen can be performed in order to avoid competition and verify the hits.

## BRD4<sup>2</sup>

- BRD4 is a known target for various forms of carcinoma.
- Acetylation of histone lysines has a key role in regulating chromatin architecture and transcription.
- BRD4 „reads“ lysine acetylation state through binding to it. BRD4 is a member of BET family of bromodomains.
- The goal of studies on BRD4 is to find a small molecule which will selectively prevent the interaction of BRD4 with acetylated lysine without affecting the function of other bromodomain-containing proteins.




**Figure 1.** X-ray structure of BRD4 with known binder I-BET762 (3P50.pdb)<sup>3</sup>

## Experimental

- All NMR spectra were recorded at 25 °C on Bruker Avance III 600 spectrometer using the inverse 5 mm room temperature probe.
- A known binder I-BET762 was used to optimise the experimental conditions of the screen.
- The DMSO-d<sub>6</sub> stock solutions of the fragment library were at a concentration of 100 mM. The final fragment concentration in TRIS buffer was 3.25 mM and the protein 6.5 μM (the ratio of 1 : 500).
- The STD NMR spectra were acquired using a sequence provided by Bruker BioSpin. Selective saturation of BRD4 was performed using Gauss G3 cascade pulse in duration of 3 s and on-resonance frequency of -1 ppm. The excitation sculpting scheme was used to suppress the H<sub>2</sub>O signal while relaxation filtering was employed to suppress protein resonances. An on-resonance frequency and pulse selectivity check was performed on each sample by acquisition of STD NMR spectra in absence of protein in the sample.
- 18 fragments (Table 1) were screened, the results interpreted as binding or non-binding events. Figure 2 shows the examples of STD NMR spectra belonging to a binder and a non-binder.



## Results



**Figure 2.** A binder (fragment 9) vs. non-binder (fragment 17): a) <sup>1</sup>H spectra; b) STD NMR spectra with BRD4; c) STD NMR spectra in absence of BRD4; all in TRIS buffer at 25 °C


## Conclusions

- Structure integrity and solubility check was performed under screening conditions prior to the screen, resulting in four discarded fragments.
- STD NMR was tested as a fragment screening method against BRD4. A known binder I-BET762 was used to adjust the experimental conditions of the screen. The result of the screen were five unambiguous and two possible binders.
- Comparison with SPR data revealed a good correlation between the techniques identifying three fragments which qualified as orthogonalized binders: fragments 3, 9 and 10.
- Experimentally determined protein-ligand crystal data was obtained for two out of four NMR hits.
- STD NMR screen revealed an additional two weak binders (fragments 12 and 13) undetected by other techniques that warrant further investigation in fragment-to-lead chemistry.

## References

- 1) M. Mayer, B. Meyer, *Angew. Chem. Int. Ed.* 38 (1999) 1784–1788.
- 2) D. S. Hewings, O. Fedorov, P. Filippakopoulos, S. Martin, J. Picaud, A. Tumber, C. Wells, M. M. Olcina, K. Freeman, A. Gill, A. Ritchie, D. W. Sheppard, A. J. Russell, E. M. Hammond, S. Knapp, P. E. Brennan, S. J. Conway, *J. Med. Chem.* 56 (2013) 3217–3227.
- 3) E. Nicodeme, K. L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C. Chang, R. Chandwani, I. Marazzi, P. Wilson, H. Coste, J. White, H. Kirilovsky, C. M. Rice, J. M. Lora, R. K. Prihoda, K. Lee, A. Tarakhovskiy, *Nature* 468 (2010) 1119–1123.
- 4) A. Gill, A. J. Ritchie, D. W. Sheppard, D. Hay, D. S. Hewings, P. Filippakopoulos, S. Picaud, O. Fedorov, S. J. Conway, P. Brennan, S. Knapp, Kinetic assessment of BRD4 inhibitors (2012) BioFocus poster
- 5) P. Hubbard, A. Ritchie, S. Hughes, M. Lipkin, W. Blackaby, A. MacLeod, A crystallographic-based fragment screen against human BRD4 bromodomain 1 (2013) BioFocus poster
- 6) Fidelta Data Sheet „Secondary Fragment Screen on BRD4 using NMR Spectroscopy“, 21st February 2014

## Comparison: STD NMR, SPR & X-ray



**Table 1.** Comparison of STD NMR results (Fidelta) with SPR<sup>4</sup> and X-ray<sup>5</sup> data (BioFocus)<sup>6</sup>

	NMR	SPR	X-ray
I-BET762	YES	YES	YES
FRG 2	NO*	YES	NT
FRG 3	YES*	YES	NT
FRG 4	NT**	YES	NT
FRG 5	NO	Non specific	NT
FRG 6	NO	NO	NT
FRG 7	POSSIBLE	Non specific	NT
FRG 8	NO*	YES	NO
FRG 9	YES	YES	YES
FRG 10	YES	YES	NT
FRG 11	NT**	Non specific	YES
FRG 12	YES	NO	NO
FRG 13	YES	NO	NO
FRG 14	NT**	Non specific	YES
FRG 15	NT**	Non specific	NT
FRG 16	POSSIBLE	NT	YES
FRG 17	NO	NT	NO
FRG 18	NO	NT	NO

\*low solubility under experimental conditions  
\*\*not soluble under experimental conditions  
NT=not tested

## Acknowledgements

- The author would like to thank the colleagues in BioFocus for sharing their SPR and X-ray results allowing the method comparison.